

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普华和顺集团公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

INSIDE INFORMATION ADOPTION OF REVISED DIVIDEND POLICY

ADOPTION OF REVISED DIVIDEND POLICY

The Board is pleased to announce that it has approved and adopted the Revised Dividend Policy with effect from August 16, 2023. According to the Revised Dividend Policy, the Board intends to distribute no less than 70% of the profit attributable to shareholders of the Company for a financial year as dividends, subject to the conditions and factors thereunder.

This announcement is made by PW Medtech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) is pleased to announce that it has approved and adopted a revised dividend policy (the “**Revised Dividend Policy**”) with effect from August 16, 2023.

According to the Revised Dividend Policy, in recommending or declaring dividends, the Company shall maintain adequate cash reserves for meeting its working capital requirements and future growth as well as its shareholder value. The Board intends to distribute no less than 70% of the profit attributable to shareholders of the Company for a financial year as dividends pursuant to the Revised Dividend Policy. The Board has the discretion to declare and distribute dividends to the Shareholders (the “**Shareholders**”), subject to the articles of association of the Company (the “**Articles**”), all applicable laws and regulations and the Revised Dividend Policy. The Board shall also take into account the following factors of the Group when considering the declaration and payment of dividends:

- (a) financial results;
- (b) cash flow situation;
- (c) business conditions and strategies;

- (d) future operations and earnings;
- (e) capital requirements and expenditure plans;
- (f) interests of Shareholders;
- (g) any restrictions on payment of dividends; and
- (h) any other factors that the Board may consider relevant.

Depending on the financial conditions of the Company and the Group and the conditions and factors as set out above, dividends may be proposed and/or declared by the Board for a financial year or period:

- (a) interim dividend;
- (b) final dividend;
- (c) special dividend; and
- (d) any distribution of net profits that the Board may deem appropriate.

Any final dividend for a financial year will be subject to shareholders' approval. The Company may declare and pay dividends by way of cash or scrip or by other means that the Board considers appropriate. Any dividend unclaimed shall be forfeited and shall revert to the Company in accordance with the Articles.

The Board will review the Revised Dividend Policy as appropriate from time to time.

Shareholders and potential investors should exercise caution when dealing in the shares of the Company.

By order of the Board
PW Medtech Group Limited
普华和顺集团公司
Yue'e Zhang
Chairman & Chief Executive Officer

Hong Kong, August 16, 2023

As at the date of this announcement, the Board comprises one executive director, namely, Ms. Yue'e Zhang; two non-executive directors, namely Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.